Revumenib: a new era in acute leukemia treatment. Academic Article uri icon

Overview

abstract

  • The AUGMENT-101 clinical trial reported that the use of revumenib led to improved overall survival (OS) and complete remission (CR)/CR with partial hematologic recovery (CRh) in patients with acute leukemias and has released updated data with longer follow-up of Phase 2 results. Additionally, revumenib has received FDA approval for its use in relapsed or refractory (r/r) lysine methyltransferase 2A rearranged (KMT2A-r) acute leukemias.

publication date

  • January 24, 2025

Research

keywords

  • Antineoplastic Agents
  • Leukemia
  • Leukemia, Myeloid, Acute

Identity

Scopus Document Identifier

  • 85215994059

Digital Object Identifier (DOI)

  • 10.1016/j.trecan.2025.01.006

PubMed ID

  • 39863449

Additional Document Info

volume

  • 11

issue

  • 2